About GenMark Diagnostics (NASDAQ:GNMK)
GenMark Diagnostics, Inc. is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology. It offers four Food and Drug Administration (FDA)-cleared diagnostic tests which run on its XT-8 instrument; its Respiratory Viral Panel; its Cystic Fibrosis Genotyping Test; its Warfarin Sensitivity Test, and its Thrombophilia Risk Test. It also offers a Hepatitis C (HCV) genotyping test and associated custom manufactured reagents, as well as a 2C19 Genotyping Test, versions of which are available for use with its XT-8 instrument for research use only (RUO). Its XT-8 and ePlex test cartridges utilize the combination of distinct electrodes and multiple signal probes to detect dozens of target biomarkers from a single sample, thereby enabling highly multiplexed testing.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GNMK
CUSIPN/A
Phone760-448-4300
Debt
Debt-to-Equity Ratio0.29%
Current Ratio3.44%
Quick Ratio3.04%
Price-To-Earnings
Trailing P/E Ratio-5.09
Forward P/E Ratio-8.11
P/E GrowthN/A
Sales & Book Value
Annual Sales$52.52 million
Price / Sales6.50
Cash FlowN/A
Price / CashN/A
Book Value$1.29 per share
Price / Book4.78
Profitability
EPS (Most Recent Fiscal Year)($1.21)
Net Income$-61,850,000.00
Net Margins-117.77%
Return on Equity-91.14%
Return on Assets-53.72%
Miscellaneous
Employees517
Outstanding Shares55,410,000
GenMark Diagnostics (NASDAQ:GNMK) Frequently Asked Questions
What is GenMark Diagnostics' stock symbol?
GenMark Diagnostics trades on the NASDAQ under the ticker symbol "GNMK."
How were GenMark Diagnostics' earnings last quarter?
GenMark Diagnostics, Inc (NASDAQ:GNMK) announced its quarterly earnings data on Tuesday, February, 27th. The medical equipment provider reported ($0.27) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.26) by $0.01. The medical equipment provider had revenue of $16.02 million for the quarter, compared to the consensus estimate of $15.82 million. GenMark Diagnostics had a negative net margin of 117.77% and a negative return on equity of 91.14%. View GenMark Diagnostics' Earnings History.
When is GenMark Diagnostics' next earnings date?
What price target have analysts set for GNMK?
6 analysts have issued 1-year price objectives for GenMark Diagnostics' shares. Their predictions range from $8.00 to $13.00. On average, they expect GenMark Diagnostics' stock price to reach $10.60 in the next year. View Analyst Ratings for GenMark Diagnostics.
What are Wall Street analysts saying about GenMark Diagnostics stock?
Here are some recent quotes from research analysts about GenMark Diagnostics stock:
- 1. According to Zacks Investment Research, "GenMark Diagnostics, Inc. is a molecular diagnostics company focused on developing and commercializing its proprietary eSensor(R) detection technology. The eSensor® XT-8 system is the second generation in GenMark Dx's eSensor® platform, utilizing electrochemical detection technology to detect nucleic acids on a microarray. The XT-8 System enables multiplex detection of DNA and RNA targets. The Company has developed four diagnostic tests for use with its XT-8 System. Its Cystic Fibrosis Genotyping Test, which detects pre-conception risks of cystic fibrosis, and its Warfarin Sensitivity Test, which determines an individual's ability to metabolize the oral anticoagulant warfarin, have received FDA clearance. It has also developed a Respiratory Viral Panel Test, which detects the presence of major respiratory viruses, and a Thrombosis Risk Test, which detects an individual's increased risk of blood clots. GenMark Diagnostics, Inc. is based in Pasadena, California. " (1/25/2018)
- 2. Needham & Company LLC analysts commented, "On 1/9/18, GNMK preannounced above consensus 4Q17 revenue and disclosed that it ended 2017 with 196 ePlex placements. GNMK also announced that it has launched the ePlex NP which is targeted at lower volume customers (particularly in Europe) and noted that the ePlex NP drove additional placements in 4Q17. We expect the ePlex launch to accelerate GNMK’s revenue growth and drive upside to consensus in 2018 and we reiterate our Buy rating." (1/19/2018)
- 3. BTIG Research analysts commented, "The fact that ACOR announced this morning that it will discontinue the tozadenant program (stopping dosing in all currently enrolled studies) came as little surprise following last week’s disclosure of safety issues (our thoughts here). Timing was the only marginal surprise, but based on additional analyses, the company determined that the recently instituted weekly white blood cell count screening may not be adequate to fully ensure the safety of patients. Though this morning’s headline has little incremental impact, it does highlight the added pressure on Inbrija (which is delayed itself following the RTF earlier this year) and formally removes the potential for near- term leverage in the business. Maintain Neutral." (11/20/2017)
Who are some of GenMark Diagnostics' key competitors?
Some companies that are related to GenMark Diagnostics include Anika Therapeutics (ANIK), Tactile Systems Technology (TCMD), SurModics (SRDX), Inovio Pharmaceuticals (INO), Accuray (ARAY), Utah Medical Products (UTMD), Antares Pharma (ATRS), Endologix (ELGX), Tandem Diabetes Care (TNDM), Pulse Biosciences (PLSE), T2 Biosystems (TTOO), Orthopediatrics (KIDS), Cytosorbents (CTSO), Nuvectra (NVTR), SeaSpine (SPNE), Iradimed (IRMD), Restoration Robotics (HAIR) and Apollo Endosurgery (APEN).
Who are GenMark Diagnostics' key executives?
GenMark Diagnostics' management team includes the folowing people:
- James Charles Fox Ph.D., Independent Chairman of the Board (Age 63)
- Hany Massarany, President, Chief Executive Officer, Director (Age 55)
- Scott Mendel, Chief Financial Officer (Age 50)
- Eric Stier, Senior Vice President, General Counsel, Secretary (Age 41)
- Jennifer Anne Williams, Senior Vice President - Human Resources (Age 43)
- Michael W. Gleeson, Senior Vice President, North American Commercial Operations (Age 42)
- Jon Faiz Kayyem Ph.D., Senior Vice President - Research and Development (Age 53)
- James B. McNally, Senior Vice President, Marketing and Business Development (Age 37)
- Michael S. Kagnoff, Director (Age 48)
- Daryl Jay Faulkner, Independent Director (Age 68)
Has GenMark Diagnostics been receiving favorable news coverage?
News stories about GNMK stock have trended somewhat positive this week, Accern Sentiment Analysis reports. Accern scores the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. GenMark Diagnostics earned a media sentiment score of 0.22 on Accern's scale. They also assigned media headlines about the medical equipment provider an impact score of 45.03 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
Who are GenMark Diagnostics' major shareholders?
GenMark Diagnostics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include
PRUDENTIAL FINANCIAL INC
(3.10%). Company insiders that own GenMark Diagnostics stock include Eric Stier, Hany Massarany, Ingo Chakravarty, Jennifer Anne Williams, Jon Faiz Kayyem, Lisa M Giles, Michael Gleeson, Michael Kagnoff and Scott Mendel. View Institutional Ownership Trends for GenMark Diagnostics.
How do I buy shares of GenMark Diagnostics?
Shares of GNMK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is GenMark Diagnostics' stock price today?
One share of GNMK stock can currently be purchased for approximately $6.16.
How big of a company is GenMark Diagnostics?
GenMark Diagnostics has a market capitalization of $357.41 million and generates $52.52 million in revenue each year. The medical equipment provider earns $-61,850,000.00 in net income (profit) each year or ($1.21) on an earnings per share basis. GenMark Diagnostics employs 517 workers across the globe.
How can I contact GenMark Diagnostics?
GenMark Diagnostics' mailing address is 5964 LA PLACE COURT, CARLSBAD CA, 92008. The medical equipment provider can be reached via phone at 760-448-4300 or via email at [email protected]
MarketBeat Community Rating for GenMark Diagnostics (GNMK)
MarketBeat's community ratings are surveys of what our community members think about GenMark Diagnostics and other stocks. Vote "Outperform" if you believe GNMK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNMK will underperform the S&P 500 over the long term. You may vote once every thirty days.
GenMark Diagnostics (NASDAQ:GNMK) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for GenMark Diagnostics in the last 12 months. Their average twelve-month price target is $10.60, suggesting that the stock has a possible upside of 72.08%. The high price target for GNMK is $13.00 and the low price target for GNMK is $8.00. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.83 | 2.83 | 2.83 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $10.60 | $10.60 | $11.80 | $14.40 |
| Price Target Upside: | 72.08% upside | 118.56% upside | 150.53% upside | 83.67% upside |
GenMark Diagnostics (NASDAQ:GNMK) Consensus Price Target History
GenMark Diagnostics (NASDAQ:GNMK) Analyst Ratings History
Show:
(Data available from 4/20/2016 forward)
GenMark Diagnostics (NASDAQ:GNMK) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
GenMark Diagnostics (NASDAQ GNMK) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 7.50%
GenMark Diagnostics (NASDAQ GNMK) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/12/2018 | Eric Stier | SVP | Sell | 10,000 | $5.46 | $54,600.00 | 197,502 |  |
| 3/2/2018 | Eric Stier | SVP | Sell | 341 | $4.00 | $1,364.00 | 207,502 | |
| 3/1/2018 | Michael Kagnoff | Director | Buy | 10,000 | $4.22 | $42,200.00 | 74,413 | |
| 2/26/2018 | Hany Massarany | Insider | Sell | 17,300 | $4.17 | $72,141.00 | 722,190 | |
| 2/26/2018 | Jennifer Anne Williams | SVP | Sell | 4,911 | $4.17 | $20,478.87 | 227,122 | |
| 2/26/2018 | Scott Mendel | CFO | Sell | 6,275 | $4.17 | $26,166.75 | 246,161 | |
| 2/21/2018 | Jennifer Anne Williams | SVP | Sell | 5,147 | $4.40 | $22,646.80 | 149,342 | |
| 2/20/2018 | Hany Massarany | Insider | Sell | 6,584 | $4.37 | $28,772.08 | 357,190 | |
| 2/20/2018 | Scott Mendel | CFO | Sell | 2,304 | $4.37 | $10,068.48 | 129,161 | |
| 2/14/2018 | Scott Mendel | CFO | Sell | 1,391 | $4.54 | $6,315.14 | 131,465 | |
| 2/2/2018 | Eric Stier | SVP | Sell | 401 | $5.13 | $2,057.13 | 134,108 | |
| 2/2/2018 | Hany Massarany | Insider | Sell | 1,252 | $5.13 | $6,422.76 | | |
| 2/2/2018 | Scott Mendel | CFO | Sell | 258 | $5.13 | $1,323.54 | 132,856 | |
| 1/23/2018 | Eric Stier | SVP | Sell | 4,000 | $5.05 | $20,200.00 | 134,509 | |
| 12/4/2017 | Michael Gleeson | SVP | Sell | 499 | $4.70 | $2,345.30 | 287,140 | |
| 11/20/2017 | Hany Massarany | Insider | Sell | 8,252 | $4.74 | $39,114.48 | 362,957 | |
| 11/20/2017 | Jennifer Anne Williams | SVP | Sell | 2,719 | $4.74 | $12,888.06 | 152,709 | |
| 11/20/2017 | Scott Mendel | CFO | Sell | 2,879 | $4.74 | $13,646.46 | 133,114 | |
| 11/14/2017 | Scott Mendel | CFO | Sell | 1,777 | $4.71 | $8,369.67 | 135,993 | |
| 11/6/2017 | Michael Kagnoff | Director | Buy | 20,000 | $4.13 | $82,600.00 | 64,413 | |
| 11/2/2017 | Eric Stier | SVP | Sell | 367 | $7.24 | $2,657.08 | 141,112 | |
| 11/2/2017 | Hany Massarany | Insider | Sell | 1,588 | $7.24 | $11,497.12 | 371,209 | |
| 11/2/2017 | Scott Mendel | CFO | Sell | 326 | $7.24 | $2,360.24 | 137,770 | |
| 10/2/2017 | Eric Stier | SVP | Sell | 2,750 | $9.60 | $26,400.00 | | |
| 9/15/2017 | Jennifer Anne Williams | SVP | Sell | 38,681 | $9.08 | $351,223.48 | 155,889 | |
| 9/11/2017 | Michael Kagnoff | Director | Buy | 2,500 | $9.15 | $22,875.00 | 44,413 | |
| 9/5/2017 | Eric Stier | SVP | Sell | 311 | $9.75 | $3,032.25 | 144,229 | |
| 8/21/2017 | Hany Massarany | Insider | Sell | 8,311 | $9.45 | $78,538.95 | 372,797 | |
| 8/21/2017 | Michael Gleeson | SVP | Sell | 1,933 | $9.45 | $18,266.85 | 291,223 | |
| 8/21/2017 | Scott Mendel | CFO | Sell | 2,898 | $9.45 | $27,386.10 | 138,096 | |
| 8/15/2017 | Scott Mendel | CFO | Sell | 1,752 | $10.16 | $17,800.32 | 140,994 | |
| 8/2/2017 | Hany Massarany | Insider | Sell | 1,629 | $10.33 | $16,827.57 | | |
| 8/2/2017 | Jon Faiz Kayyem | SVP | Sell | 138 | $10.33 | $1,425.54 | 200,719 | |
| 8/2/2017 | Scott Mendel | CFO | Sell | 333 | $10.33 | $3,439.89 | 142,746 | |
| 6/2/2017 | Michael Gleeson | SVP | Sell | 357 | $12.89 | $4,601.73 | 293,565 | |
| 5/19/2017 | Hany Massarany | Insider | Sell | 8,239 | $12.89 | $106,200.71 | | |
| 5/19/2017 | Michael Gleeson | SVP | Sell | 1,916 | $12.89 | $24,697.24 | 293,922 | |
| 5/19/2017 | Scott Mendel | CFO | Sell | 2,135 | $12.89 | $27,520.15 | 143,079 | |
| 5/16/2017 | Scott Mendel | CFO | Sell | 1,268 | $13.43 | $17,029.24 | | |
| 5/2/2017 | Eric Stier | SVP | Sell | 362 | $13.34 | $4,829.08 | 148,825 | |
| 5/2/2017 | Hany Massarany | Insider | Sell | 1,571 | $13.34 | $20,957.14 | | |
| 5/2/2017 | Scott Mendel | CFO | Sell | 232 | $13.34 | $3,094.88 | 162,529 | |
| 3/3/2017 | Michael Gleeson | SVP | Sell | 353 | $12.29 | $4,338.37 | 296,757 | |
| 2/21/2017 | Hany Massarany | Insider | Sell | 33,537 | $10.08 | $338,052.96 | | |
| 2/21/2017 | Jon Faiz Kayyem | SVP | Sell | 5,250 | $10.08 | $52,920.00 | 154,079 | |
| 2/21/2017 | Scott Mendel | CFO | Sell | 8,595 | $10.08 | $86,637.60 | 102,761 | |
| 2/2/2017 | Hany Massarany | Insider | Sell | 1,142 | $11.58 | $13,224.36 | | |
| 2/2/2017 | Jennifer Anne Williams | SVP | Sell | 332 | $11.58 | $3,844.56 | 161,930 | |
| 2/2/2017 | Scott Mendel | CFO | Sell | 235 | $11.58 | $2,721.30 | | |
| 1/19/2017 | Hany Massarany | Insider | Sell | 27,124 | $12.47 | $338,236.28 | 298,500 | |
| 1/19/2017 | Michael Gleeson | SVP | Sell | 9,569 | $12.47 | $119,325.43 | 252,558 | |
| 1/19/2017 | Scott Mendel | CFO | Sell | 9,098 | $12.47 | $113,452.06 | 142,058 | |
| 12/5/2016 | Jennifer Anne Williams | SVP | Sell | 336 | $11.31 | $3,800.16 | | |
| 12/2/2016 | Michael Gleeson | SVP | Sell | 357 | $11.30 | $4,034.10 | | |
| 11/22/2016 | Michael Kagnoff | Director | Buy | 2,000 | $11.80 | $23,600.00 | 35,048 | |
| 11/14/2016 | Michael Kagnoff | Director | Buy | 2,000 | $12.50 | $25,000.00 | 33,048 | |
| 11/2/2016 | Hany Massarany | Insider | Sell | 1,148 | $10.30 | $11,824.40 | | |
| 11/2/2016 | Michael Gleeson | SVP | Sell | 400 | $10.30 | $4,120.00 | 245,653 | |
| 9/7/2016 | Hany Massarany | Insider | Sell | 1,186 | $8.69 | $10,306.34 | | |
| 9/7/2016 | Jennifer Anne Williams | SVP | Sell | 523 | $8.69 | $4,544.87 | 164,080 | |
| 9/2/2016 | Jon Faiz Kayyem | SVP | Sell | 133 | $8.62 | $1,146.46 | 152,437 | |
| 8/29/2016 | Jennifer Anne Williams | SVP | Sell | 24,172 | $8.63 | $208,604.36 | 164,937 | |
| 8/22/2016 | Michael Gleeson | SVP | Sell | 7,500 | $9.00 | $67,500.00 | 246,934 | |
| 8/12/2016 | Lisa M Giles | Director | Buy | 823 | $9.40 | $7,736.20 | 16,710 | |
| 8/2/2016 | Eric Stier | SVP | Sell | 367 | $9.88 | $3,625.96 | 110,681 | |
| 8/2/2016 | Hany Massarany | Insider | Sell | 1,147 | $9.88 | $11,332.36 | | |
| 6/7/2016 | Hany Massarany | CEO | Sell | 1,188 | $8.98 | $10,668.24 | 292,640 | |
| 6/7/2016 | Michael Gleeson | SVP | Sell | 868 | $8.80 | $7,638.40 | 255,358 | |
| 6/3/2016 | Ingo Chakravarty | SVP | Sell | 184 | $8.53 | $1,569.52 | 139,229 | |
| 5/9/2016 | Ingo Chakravarty | SVP | Sell | 582 | $5.42 | $3,154.44 | 137,913 | |
| 5/2/2016 | Eric Stier | SVP | Sell | 363 | $5.79 | $2,101.77 | 111,560 | |
| 5/2/2016 | Hany Massarany | CEO | Sell | 1,160 | $5.79 | $6,716.40 | 295,765 | |
| 3/10/2016 | Michael Kagnoff | Director | Buy | 2,500 | $4.90 | $12,250.00 | 22,761 | |
| 3/7/2016 | Hany Massarany | CEO | Sell | 1,193 | $5.76 | $6,871.68 | 298,768 | |
| 3/7/2016 | Michael Gleeson | SVP | Sell | 559 | $5.76 | $3,219.84 | 254,598 | |
| 3/2/2016 | Eric Stier | SVP | Sell | 365 | $4.87 | $1,777.55 | 112,189 | |
| 2/9/2016 | Ingo Chakravarty | SVP | Sell | 697 | $5.04 | $3,512.88 | 58,379 | |
| 2/3/2016 | Hany Massarany | CEO | Sell | 9,173 | $4.99 | $45,773.27 | | |
| 2/3/2016 | Michael Gleeson | SVP | Sell | 3,083 | $4.99 | $15,384.17 | 176,353 | |
| 1/21/2016 | Hany Massarany | CEO | Sell | 648 | $6.80 | $4,406.40 | 79,557 | |
| 1/21/2016 | Michael Gleeson | SVP | Sell | 227 | $6.80 | $1,543.60 | 179,436 | |
| 12/8/2015 | Eric Stier | SVP | Sell | 240 | $7.26 | $1,742.40 | 39,660 | |
| 12/8/2015 | Hany Massarany | CEO | Sell | 1,735 | $7.26 | $12,596.10 | 79,557 | |
| 12/3/2015 | Hany Massarany | CEO | Sell | 3,571 | $7.71 | $27,532.41 | 82,682 | |
| 12/3/2015 | Michael Gleeson | SVP | Sell | 1,664 | $7.62 | $12,679.68 | 179,707 | |
| 11/3/2015 | Lisa M Giles | Director | Buy | 4,000 | $6.60 | $26,400.00 | 8,213 | |
| 10/30/2015 | Michael Kagnoff | Director | Buy | 5,000 | $6.70 | $33,500.00 | 20,261 | |
| 10/30/2015 | Scott Mendel | CFO | Buy | 10,000 | $6.47 | $64,700.00 | 52,145 | |
| 10/29/2015 | Daryl Faulkner | Director | Buy | 4,000 | $7.33 | $29,320.00 | 53,013 | |
| 9/15/2015 | Jennifer Anne Williams | SVP | Sell | 14,245 | $9.98 | $142,165.10 | 118,547 | |
| 9/14/2015 | Jennifer Anne Williams | SVP | Sell | 9,245 | $10.00 | $92,450.00 | 118,547 | |
| 9/11/2015 | Hany Massarany | CEO | Sell | 1,683 | $9.64 | $16,224.12 | 89,557 | |
| 9/11/2015 | Jennifer Anne Williams | SVP | Sell | 18,280 | $9.99 | $182,617.20 | 132,792 | |
| 9/4/2015 | Jennifer Anne Williams | SVP | Sell | 1,867 | $9.59 | $17,904.53 | 151,072 | |
| 9/2/2015 | Hany Massarany | CEO | Sell | 3,865 | $9.62 | $37,181.30 | 92,682 | |
| 8/24/2015 | Scott Mendel | CFO | Buy | 10,000 | $9.10 | $91,000.00 | 52,145 | |
| 6/16/2015 | Hany Massarany | CEO | Sell | 1,698 | $9.12 | $15,485.76 | | |
| 6/4/2015 | Michael Gleeson | SVP | Sell | 1,595 | $9.55 | $15,232.25 | | |
| 6/3/2015 | Hany Massarany | CEO | Sell | 3,486 | $9.47 | $33,012.42 | | |
| 4/9/2015 | Hany Massarany | CEO | Sell | 5,942 | $11.52 | $68,451.84 | | |
| 3/13/2015 | Jennifer Anne Williams | SVP | Sell | 30,000 | $12.56 | $376,800.00 | | |
| 3/11/2015 | Hany Massarany | CEO | Sell | 28,110 | $11.88 | $333,946.80 | | |
| 3/11/2015 | Jeffrey Alan Hawkins | SVP | Sell | 6,832 | $12.01 | $82,052.32 | | |
| 3/10/2015 | Jennifer Anne Williams | SVP | Sell | 722 | $11.83 | $8,541.26 | | |
| 3/10/2015 | Michael Kagnoff | Director | Buy | 5,000 | $11.84 | $59,200.00 | | |
| 3/9/2015 | Ingo Chakravarty | SVP | Sell | 3,310 | $12.06 | $39,918.60 | | |
| 1/22/2015 | Hany Massarany | CEO | Sell | 5,982 | $12.88 | $77,048.16 | | |
| 1/7/2015 | Hany Massarany | CEO | Sell | 4,858 | $13.00 | $63,154.00 | | |
| 12/16/2014 | Kevin C Oboyle | Director | Sell | 291 | $12.40 | $3,608.40 | | |
| 12/15/2014 | Eric Stier | SVP | Sell | 235 | $12.51 | $2,939.85 | | |
| 12/15/2014 | Hany Massarany | CEO | Sell | 1,700 | $12.51 | $21,267.00 | | |
| 12/4/2014 | Hany Massarany | CEO | Sell | 3,300 | $12.06 | $39,798.00 | | |
| 12/4/2014 | Jeffrey Alan Hawkins | SVP | Sell | 1,350 | $12.06 | $16,281.00 | | |
| 10/31/2014 | Jon Faiz Kayyem | SVP | Sell | 6,000 | $11.01 | $66,060.00 | | |
| 10/8/2014 | Hany Massarany | CEO | Sell | 5,804 | $9.00 | $52,236.00 | | |
| 10/7/2014 | Michael Gleeson | SVP | Sell | 55 | $9.10 | $500.50 | | |
| 9/12/2014 | Hany Massarany | CEO | Sell | 1,678 | $9.86 | $16,545.08 | | |
| 9/5/2014 | Hany Massarany | CEO | Sell | 3,795 | $10.04 | $38,101.80 | | |
| 9/5/2014 | Michael Gleeson | SVP | Sell | 1,833 | $10.04 | $18,403.32 | | |
| 8/7/2014 | Michael Gleeson | SVP | Sell | 52 | $11.15 | $579.80 | | |
| 7/1/2014 | Jon Faiz Kayyem | SVP | Sell | 6,000 | $13.60 | $81,600.00 | | |
| 6/11/2014 | Hany Massarany | CEO | Sell | 1,115 | $11.64 | $12,978.60 | | |
| 6/5/2014 | Jon Faiz Kayyem | SVP | Sell | 1,483 | $10.69 | $15,853.27 | | |
| 6/3/2014 | Hany Massarany | CEO | Sell | 2,700 | $10.67 | $28,809.00 | | |
| 5/29/2014 | Kevin C Oboyle | Director | Sell | 1,603 | $10.98 | $17,600.94 | | |
| 5/28/2014 | Jon Faiz Kayyem | SVP | Sell | 6,000 | $11.06 | $66,360.00 | | |
| 5/8/2014 | Richard Slansky | CFO | Sell | 2,302 | $9.26 | $21,316.52 | 79,534 | |
| 4/9/2014 | Hany Massarany | CEO | Sell | 3,985 | $9.87 | $39,331.95 | 195,583 | |
| 3/26/2014 | Jennifer Anne Williams | SVP | Sell | 30,195 | $9.97 | $301,044.15 | 185,023 | |
| 3/5/2014 | Jon Faiz Kayyem | SVP | Sell | 7,355 | $12.46 | $91,643.30 | 98,800 | |
| 1/16/2014 | Jon Faiz Kayyem | SVP | Sell | 50,000 | $14.05 | $702,500.00 | 106,155 | |
| 1/7/2014 | Hany Massarany | CEO | Sell | 4,698 | $13.31 | $62,530.38 | 229,772 | |
| 12/6/2013 | Michael Gleeson | SVP | Sell | 2,211 | $11.14 | $24,630.54 | 185,649 | |
| 12/4/2013 | Hany Massarany | CEO | Sell | 3,968 | $11.14 | $44,203.52 | 240,816 | |
| 10/9/2013 | Hany Massarany | CEO | Sell | 3,925 | $12.05 | $47,296.25 | 247,693 | |
| 10/1/2013 | Jon Faiz Kayyem | SVP | Sell | 6,000 | $12.14 | $72,840.00 | | |
| 9/4/2013 | Jeffrey Alan Hawkins | SVP | Sell | 1,890 | $11.60 | $21,924.00 | 94,639 | |
| 9/3/2013 | Hany Massarany | CEO | Sell | 2,354 | $11.60 | $27,306.40 | 506,559 | |
| 9/3/2013 | Jon Faiz Kayyem | SVP | Sell | 1,545 | $11.60 | $17,922.00 | 106,806 | |
| 8/20/2013 | Jon Faiz Kayyem | SVP | Sell | 1,310 | $10.15 | $13,296.50 | 108,351 | |
| 7/1/2013 | Jon Faiz Kayyem | SVP | Sell | 6,000 | $10.40 | $62,400.00 | | |
(Data available from 1/1/2013 forward)
GenMark Diagnostics (NASDAQ GNMK) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | GenMark Diagnostics (GNMK) Cut to Sell at BidaskClub
www.americanbankingnews.com - April 18 at 6:22 PM |
 | GenMark Diagnostics Schedules First Quarter Financial Results Conference Call for May 1, 2018
finance.yahoo.com - April 17 at 6:01 PM |
| GenMark Diagnostics (GNMK) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - April 16 at 8:40 PM |
| Brokerages Anticipate GenMark Diagnostics, Inc (GNMK) Will Announce Quarterly Sales of $17.35 Million
www.americanbankingnews.com - April 14 at 5:35 AM |
| GenMark Diagnostics, Inc (GNMK) SVP Sells $54,600.00 in Stock
www.americanbankingnews.com - April 13 at 7:11 PM |
 | This Morning's Technical Outlook on Medical Equipment Stocks -- Edwards Lifesciences, GenMark Diagnostics, Globus Medical, and InspireMD
www.bizjournals.com - April 13 at 8:15 AM |
| GenMark Diagnostics' (GNMK) "Buy" Rating Reaffirmed at Canaccord Genuity
www.americanbankingnews.com - April 12 at 11:52 PM |
| Brokerages Expect GenMark Diagnostics, Inc (GNMK) to Post -$0.21 EPS
www.americanbankingnews.com - April 12 at 1:13 AM |
| BidaskClub Downgrades GenMark Diagnostics (GNMK) to Sell
www.americanbankingnews.com - April 10 at 3:54 PM |
| GenMark Diagnostics (GNMK) Upgraded by BidaskClub to "Buy"
www.americanbankingnews.com - April 10 at 10:25 AM |
| Cramer Remix: Ignoring Washington negatives could benefit...
finance.yahoo.com - April 10 at 8:18 AM |
| GenMark Diagnostics, Inc (GNMK) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 8 at 7:50 AM |
| GenMark Diagnostics (GNMK) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 5 at 12:30 AM |
| GenMark Diagnostics (GNMK) Earns Buy Rating from Canaccord Genuity
www.americanbankingnews.com - April 4 at 12:34 AM |
| GenMark Diagnostics (GNMK) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 1 at 2:38 PM |
| GenMark Diagnostics (GNMK) PT Set at $11.00 by BTIG Research
www.americanbankingnews.com - March 27 at 8:34 PM |
| GenMark Diagnostics (GNMK) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - March 27 at 5:10 PM |
| GenMark Diagnostics (GNMK) Upgraded by BidaskClub to Sell
www.americanbankingnews.com - March 26 at 5:58 PM |
| -$0.21 EPS Expected for GenMark Diagnostics, Inc (GNMK) This Quarter
www.americanbankingnews.com - March 26 at 3:24 AM |
| Brokers Set Expectations for GenMark Diagnostics, Inc's Q2 2018 Earnings (GNMK)
www.americanbankingnews.com - March 20 at 8:26 AM |
| GenMark Diagnostics, Inc (GNMK) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - March 14 at 1:10 PM |
| GenMark Diagnostics (GNMK) Raised to "Sell" at BidaskClub
www.americanbankingnews.com - March 11 at 5:59 PM |
| $17.53 Million in Sales Expected for GenMark Diagnostics, Inc (GNMK) This Quarter
www.americanbankingnews.com - March 10 at 2:56 AM |
| Head to Head Comparison: ResMed (RMD) & GenMark Diagnostics (GNMK)
www.americanbankingnews.com - March 9 at 9:09 AM |
| Zacks: Brokerages Anticipate GenMark Diagnostics, Inc (GNMK) Will Post Earnings of -$0.21 Per Share
www.americanbankingnews.com - March 8 at 7:11 PM |
| Blog Exposure - Zimmer Biomet Showcased New Product and Service Innovations at American Academy of Orthopaedic Surgeons Annual Meeting 2018
finance.yahoo.com - March 8 at 8:16 AM |
| Free Post Earnings Research Report: Steris’ Revenues Grew 2%; Adjusted EPS Advanced 14%
finance.yahoo.com - March 7 at 8:12 AM |
 | What's Happening With These Medical Equipment Stocks? -- GenMark Diagnostics, Globus Medical, Masimo, and Natus Medical
www.prnewswire.com - March 6 at 8:11 AM |
| GenMark Diagnostics, Inc (GNMK) Director Buys $42,200.00 in Stock
www.americanbankingnews.com - March 5 at 7:34 PM |
| FY2018 EPS Estimates for GenMark Diagnostics, Inc (GNMK) Decreased by William Blair
www.americanbankingnews.com - March 2 at 12:50 PM |
| Canaccord Genuity Lowers GenMark Diagnostics (GNMK) Price Target to $8.00
www.americanbankingnews.com - February 28 at 5:52 PM |
| GenMark Diagnostics (GNMK) Announces Quarterly Earnings Results, Meets Estimates
www.americanbankingnews.com - February 28 at 10:58 AM |
| Insider Selling: GenMark Diagnostics, Inc (GNMK) SVP Sells 4,911 Shares of Stock
www.americanbankingnews.com - February 27 at 9:46 PM |
| GenMark Diagnostics, Inc (GNMK) CFO Sells $26,166.75 in Stock
www.americanbankingnews.com - February 27 at 9:46 PM |
| GenMark Diagnostics, Inc (GNMK) Insider Hany Massarany Sells 17,300 Shares
www.americanbankingnews.com - February 27 at 9:46 PM |
| GenMark Diagnostics Reports Fourth Quarter and Full Year 2017 Results
finance.yahoo.com - February 27 at 5:58 PM |
| $15.82 Million in Sales Expected for GenMark Diagnostics, Inc (GNMK) This Quarter
www.americanbankingnews.com - February 22 at 3:02 PM |
| Scott Mendel Sells 2,304 Shares of GenMark Diagnostics, Inc (GNMK) Stock
www.americanbankingnews.com - February 21 at 9:38 PM |
| GenMark Diagnostics, Inc (GNMK) SVP Sells $22,646.80 in Stock
www.americanbankingnews.com - February 21 at 9:38 PM |
| Hany Massarany Sells 6,584 Shares of GenMark Diagnostics, Inc (GNMK) Stock
www.americanbankingnews.com - February 21 at 9:38 PM |
| GenMark Diagnostics to Present at Upcoming Investor Conferences
finance.yahoo.com - February 21 at 5:30 PM |
| Zacks: Brokerages Expect GenMark Diagnostics, Inc (GNMK) to Post -$0.24 Earnings Per Share
www.americanbankingnews.com - February 20 at 3:08 AM |
| GenMark Diagnostics (GNMK) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - February 19 at 4:30 AM |
| GenMark Diagnostics, Inc (GNMK) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - February 17 at 9:46 AM |
| Critical Analysis: GenMark Diagnostics (GNMK) vs. Alliance HealthCare Services (AIQ)
www.americanbankingnews.com - February 14 at 12:46 PM |
| GenMark Diagnostics Schedules Fourth Quarter and Full Year 2017 Financial Results Conference Call for February 27, 2018
finance.yahoo.com - February 14 at 9:19 AM |
| Head-To-Head Analysis: Intuitive Surgical (ISRG) & GenMark Diagnostics (GNMK)
www.americanbankingnews.com - February 12 at 1:16 AM |
| GenMark Diagnostics, Inc (GNMK) Expected to Post Quarterly Sales of $15.82 Million
www.americanbankingnews.com - February 5 at 7:32 AM |
| GenMark Diagnostics, Inc (GNMK) Expected to Post Earnings of -$0.24 Per Share
www.americanbankingnews.com - February 3 at 3:12 AM |
| GenMark Diagnostics (GNMK) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 28 at 11:40 AM |
GenMark Diagnostics (NASDAQ:GNMK) SEC Filings
This page is loading this company's SEC Filings. Please wait...
GenMark Diagnostics (NASDAQ:GNMK) Income Statement, Balance Sheet and Cash Flow Statement
GenMark Diagnostics (NASDAQ GNMK) Stock Chart for Friday, April, 20, 2018
Loading chart…
